Hasselbalch HC - Search Results

1

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?

Hasselbalch HC, Holmström MO. Hasselbalch HC, et al. Semin Immunopathol. 2019 Jan;41(1):5-19. doi: 10.1007/s00281-018-0700-2. Epub 2018 Sep 10. Semin Immunopathol. 2019. PMID: 30203226 Free PMC article. Review.

2

Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?

Hasselbalch HC, Riley CH. Hasselbalch HC, et al. Leuk Res. 2006 Oct;30(10):1217-25. doi: 10.1016/j.leukres.2005.12.018. Epub 2006 Feb 17. Leuk Res. 2006. PMID: 16483650 Review.

3

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.

Larsen TS, Bjerrum OW, Pallisgaard N, Andersen MT, Møller MB, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Ann Hematol. 2008 Oct;87(10):847-50. doi: 10.1007/s00277-008-0498-4. Epub 2008 May 15. Ann Hematol. 2008. PMID: 18481066

4

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission.

Larsen TS, Møller MB, de Stricker K, Nørgaard P, Samuelsson J, Marcher C, Andersen MT, Bjerrum OW, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Hematology. 2009 Dec;14(6):331-4. doi: 10.1179/102453309X12473408860587. Hematology. 2009. PMID: 19941739 Free article.

5

Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.

Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. Hasselbalch HC, et al. Curr Drug Targets. 2011 Mar 1;12(3):392-419. doi: 10.2174/138945011794815275. Curr Drug Targets. 2011. PMID: 21143149 Review.

6

Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.

Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM. Riley CH, et al. Among authors: hasselbalch hc. Blood. 2011 Aug 25;118(8):2170-3. doi: 10.1182/blood-2011-03-340992. Epub 2011 Jun 27. Blood. 2011. PMID: 21708889 Free article.

7

The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.

Risum M, Madelung A, Bondo H, Bzorek M, Kristensen MH, Stamp IM, Hasselbalch HC. Risum M, et al. Among authors: hasselbalch hc. APMIS. 2011 Aug;119(8):498-504. doi: 10.1111/j.1600-0463.2011.02754.x. Epub 2011 Apr 17. APMIS. 2011. PMID: 21749449

8

A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.

Hasselbalch HC. Hasselbalch HC. Expert Rev Hematol. 2011 Dec;4(6):637-55. doi: 10.1586/ehm.11.63. Expert Rev Hematol. 2011. PMID: 22077528 Review.

9

Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?

Hasselbalch HC. Hasselbalch HC. Blood. 2012 Apr 5;119(14):3219-25. doi: 10.1182/blood-2011-11-394775. Epub 2012 Feb 7. Blood. 2012. PMID: 22318201 Free article.

10

Inheritance of the chronic myeloproliferative neoplasms. A systematic review.

Ranjan A, Penninga E, Jelsig AM, Hasselbalch HC, Bjerrum OW. Ranjan A, et al. Among authors: hasselbalch hc. Clin Genet. 2013 Feb;83(2):99-107. doi: 10.1111/cge.12044. Epub 2012 Nov 20. Clin Genet. 2013. PMID: 23094849

11

Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?

Hasselbalch HC. Hasselbalch HC. Leuk Res. 2013 Feb;37(2):214-20. doi: 10.1016/j.leukres.2012.10.020. Epub 2012 Nov 20. Leuk Res. 2013. PMID: 23174192 Review.

12

A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.

Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, Fernandes S, Bareford D, Knapper S, Samuelsson J, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Hasselbalch HC. Andersen CL, et al. Among authors: hasselbalch hc. Br J Haematol. 2013 Aug;162(4):498-508. doi: 10.1111/bjh.12416. Epub 2013 Jun 11. Br J Haematol. 2013. PMID: 23758082 Clinical Trial.

13

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.

Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, Larsen H, Helleberg I, Riley CH, Bjerrum OW, Rønnov-Jessen D, Møller MB, de Stricker K, Vestergaard H, Hasselbalch HC. Stauffer Larsen T, et al. Among authors: hasselbalch hc. Leuk Res. 2013 Sep;37(9):1041-5. doi: 10.1016/j.leukres.2013.06.012. Epub 2013 Jul 1. Leuk Res. 2013. PMID: 23827351

14

Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.

Hasselbalch HC. Hasselbalch HC. Expert Rev Hematol. 2014 Apr;7(2):203-16. doi: 10.1586/17474086.2013.876356. Epub 2014 Feb 13. Expert Rev Hematol. 2014. PMID: 24524202

15

Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.

Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM, Jensen MK. Riley CH, et al. Among authors: hasselbalch hc. Eur J Haematol. 2015 Mar;94(3):227-34. doi: 10.1111/ejh.12420. Epub 2014 Sep 24. Eur J Haematol. 2015. PMID: 25082025

16

The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?

Hasselbalch HC. Hasselbalch HC. Leuk Res. 2014 Oct;38(10):1230-6. doi: 10.1016/j.leukres.2014.07.006. Epub 2014 Jul 22. Leuk Res. 2014. PMID: 25149709

17

Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis.

Hasselbalch HC. Hasselbalch HC. Eur J Haematol. 2015 Feb;94(2):96-8. doi: 10.1111/ejh.12437. Eur J Haematol. 2015. PMID: 25689636 No abstract available.

18

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.

Bjørn ME, Holmström MO, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2016;57(1):125-8. doi: 10.3109/10428194.2015.1046867. Epub 2015 Sep 23. Leuk Lymphoma. 2016. PMID: 25936872

19

Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera.

Utke Rank C, Weis Bjerrum O, Larsen TS, Kjær L, de Stricker K, Riley CH, Hasselbalch HC. Utke Rank C, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2016 Feb;57(2):348-354. doi: 10.3109/10428194.2015.1049171. Epub 2015 Jun 18. Leuk Lymphoma. 2016. PMID: 25956046

20

[Status and perspectives on chronic myeloproliferative neoplasm treatment].

Ocias LF, Holmström MO, Riley CH, Andersen CL, Rønnov-Jessen D, Starklint J, Frederiksen M, Steffensen MS, Bjerrum OW, Farmer S, Mourits-Andersen T, Hasselbalch HC, Larsen TS. Ocias LF, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2015 May 4;177(19):V12140652. Ugeskr Laeger. 2015. PMID: 25967090 Free article. Review. Danish.

21

[New disease markers within the chronic myeloproliferative neoplasms].

Holmström MO, Ocias LF, Kallenbach K, Kjær L, Kristensen TK, Pallisgaard N, Petersen BL, Skov V, de Stricker K, Larsen TS, Hasselbalch HC. Holmström MO, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2015 May 4;177(19):V12140653. Ugeskr Laeger. 2015. PMID: 25967091 Free article. Review. Danish.

22

Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?

Hasselbalch HC, Silver RT. Hasselbalch HC, et al. Expert Rev Hematol. 2015 Aug;8(4):439-45. doi: 10.1586/17474086.2015.1045409. Epub 2015 May 21. Expert Rev Hematol. 2015. PMID: 25996953

23

Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera.

Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L, Straten PT, Svane IM. Riley CH, et al. Among authors: hasselbalch hc. Eur J Haematol. 2016 Jul;97(1):83-92. doi: 10.1111/ejh.12687. Epub 2015 Nov 26. Eur J Haematol. 2016. PMID: 26385526

24

Smoking as a contributing factor for development of polycythemia vera and related neoplasms.

Hasselbalch HC. Hasselbalch HC. Leuk Res. 2015 Sep 9:S0145-2126(15)30373-8. doi: 10.1016/j.leukres.2015.09.002. Online ahead of print. Leuk Res. 2015. PMID: 26463040 Review.

25

The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms.

Bjørn ME, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Mediators Inflamm. 2015;2015:648090. doi: 10.1155/2015/648090. Epub 2015 Oct 11. Mediators Inflamm. 2015. PMID: 26538833 Free PMC article. Review.

26

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Maria Vannucchi A, Cervantes F, Silver RT, Barbui T. Koschmieder S, et al. Among authors: hasselbalch hc. Leukemia. 2016 May;30(5):1018-24. doi: 10.1038/leu.2016.12. Epub 2016 Feb 8. Leukemia. 2016. PMID: 26854026 Review.

27

Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials.

Silver RT, Hasselbalch HC. Silver RT, et al. Among authors: hasselbalch hc. Hematology. 2016 Aug;21(7):387-91. doi: 10.1080/10245332.2015.1111644. Epub 2016 Feb 26. Hematology. 2016. PMID: 26900719 Free article.

28

Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.

Hansen IO, Sørensen AL, Hasselbalch HC. Hansen IO, et al. Among authors: hasselbalch hc. Eur J Haematol. 2017 Jan;98(1):75-84. doi: 10.1111/ejh.12787. Epub 2016 Sep 4. Eur J Haematol. 2017. PMID: 27471124

29

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms.

Holmström MO, Riley CH, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Leukemia. 2016 Dec;30(12):2413-2416. doi: 10.1038/leu.2016.233. Epub 2016 Aug 18. Leukemia. 2016. PMID: 27560107 No abstract available.

30

Non-invasive imaging of retinal blood flow in myeloproliferative neoplasms.

Willerslev A, Hansen MM, Klefter ON, Bjerrum OW, Hasselbalch HC, Clemmensen SN, Larsen M, Munch IC. Willerslev A, et al. Among authors: hasselbalch hc. Acta Ophthalmol. 2017 Mar;95(2):146-152. doi: 10.1111/aos.13249. Epub 2016 Sep 29. Acta Ophthalmol. 2017. PMID: 27682603 Free article.

31

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms.

Holmström MO, Hjortsø MD, Ahmad SM, Met Ö, Martinenaite E, Riley C, Straten P, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Leukemia. 2017 Feb;31(2):495-498. doi: 10.1038/leu.2016.290. Epub 2016 Oct 20. Leukemia. 2017. PMID: 27761006 No abstract available.

32

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.

Kjær L, Cordua S, Holmström MO, Thomassen M, Kruse TA, Pallisgaard N, Larsen TS, de Stricker K, Skov V, Hasselbalch HC. Kjær L, et al. Among authors: hasselbalch hc. PLoS One. 2016 Oct 20;11(10):e0165336. doi: 10.1371/journal.pone.0165336. eCollection 2016. PLoS One. 2016. PMID: 27764253 Free PMC article.

33

The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms.

Skov V, Riley CH, Thomassen M, Kjær L, Stauffer Larsen T, Bjerrum OW, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2017 Aug;58(8):1914-1921. doi: 10.1080/10428194.2016.1262032. Epub 2016 Dec 2. Leuk Lymphoma. 2017. PMID: 27911124

34

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.

Bjørn ME, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Expert Rev Hematol. 2017 May;10(5):393-404. doi: 10.1080/17474086.2017.1284583. Epub 2017 Apr 12. Expert Rev Hematol. 2017. PMID: 28402197 Review.

35

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Holmström MO, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L, Riley CH, Thor Straten P, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Leukemia. 2018 Feb;32(2):429-437. doi: 10.1038/leu.2017.214. Epub 2017 Jul 5. Leukemia. 2018. PMID: 28676668

36

Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes.

Kjaer L, Holmström MO, Cordua S, Andersen MH, Svane IM, Thomassen M, Kruse TA, Pallisgaard N, Skov V, Hasselbalch HC. Kjaer L, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2018 Apr;59(4):973-977. doi: 10.1080/10428194.2017.1359743. Epub 2017 Aug 9. Leuk Lymphoma. 2018. PMID: 28792253 No abstract available.

37

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development.

Andersen M, Sajid Z, Pedersen RK, Gudmand-Hoeyer J, Ellervik C, Skov V, Kjær L, Pallisgaard N, Kruse TA, Thomassen M, Troelsen J, Hasselbalch HC, Ottesen JT. Andersen M, et al. Among authors: hasselbalch hc. PLoS One. 2017 Aug 31;12(8):e0183620. doi: 10.1371/journal.pone.0183620. eCollection 2017. PLoS One. 2017. PMID: 28859112 Free PMC article.

38

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy.

Holmström MO, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Oncoimmunology. 2017 Aug 2;6(11):e1358334. doi: 10.1080/2162402X.2017.1358334. eCollection 2017. Oncoimmunology. 2017. PMID: 29147619 Free PMC article.

39

Myeloproliferative Neoplasms in Danish Twins.

Andersen MA, Bjerrum OW, Ranjan A, Skov V, Kruse TA, Thomassen M, Skytthe A, Hasselbalch HC, Christensen K. Andersen MA, et al. Among authors: hasselbalch hc. Acta Haematol. 2018;139(3):195-198. doi: 10.1159/000488384. Epub 2018 May 2. Acta Haematol. 2018. PMID: 29719285

40

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.

Holmström MO, Riley CH, Skov V, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Oncoimmunology. 2018 Feb 27;7(6):e1433521. doi: 10.1080/2162402X.2018.1433521. eCollection 2018. Oncoimmunology. 2018. PMID: 29872567 Free PMC article.

41

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Mikkelsen SU, Kjaer L, Bjørn ME, Knudsen TA, Sørensen AL, Andersen CBL, Bjerrum OW, Brochmann N, Fassi DE, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Pallisgaard N, Thomassen M, Skov V, Hasselbalch HC. Mikkelsen SU, et al. Among authors: hasselbalch hc. Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22. Cancer Med. 2018. PMID: 29932310 Free PMC article. Clinical Trial.

42

Cancer immune therapy for myeloid malignancies: present and future.

Holmström MO, Hasselbalch HC. Holmström MO, et al. Among authors: hasselbalch hc. Semin Immunopathol. 2019 Jan;41(1):97-109. doi: 10.1007/s00281-018-0693-x. Epub 2018 Jul 9. Semin Immunopathol. 2019. PMID: 29987478 Review.

43

Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation.

Jørgensen MA, Holmström MO, Martinenaite E, Riley CH, Hasselbalch HC, Andersen MH. Jørgensen MA, et al. Among authors: hasselbalch hc. Oncoimmunology. 2018 Jul 23;7(9):e1468957. doi: 10.1080/2162402X.2018.1468957. eCollection 2018. Oncoimmunology. 2018. PMID: 30228936 Free PMC article.

44

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ. Grinfeld J, et al. Among authors: hasselbalch hc. N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614. N Engl J Med. 2018. PMID: 30304655 Free PMC article.

45

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.

Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maié T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brümmendorf TH, Müller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sørensen AL, Holmström M, Kjær L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S. Czech J, et al. Among authors: hasselbalch hc. Leukemia. 2019 Apr;33(4):995-1010. doi: 10.1038/s41375-018-0295-6. Epub 2018 Nov 23. Leukemia. 2019. PMID: 30470838

46

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

Holmström MO, Ahmad SM, Klausen U, Bendtsen SK, Martinenaite E, Riley CH, Svane IM, Kjær L, Skov V, Ellervik C, Pallisgaard N, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Blood Cancer J. 2019 Jan 17;9(2):8. doi: 10.1038/s41408-018-0166-4. Blood Cancer J. 2019. PMID: 30655510 Free PMC article.

47

[Cancer immune therapy for the treatment of haematological malignancies].

Holmström MO, Klausen U, Jørgensen NG, Holmberg S, Grauslund J, Met Ö, Svane IM, Pedersen LM, Knudsen LM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2019 Mar 4;181(10):V06180421. Ugeskr Laeger. 2019. PMID: 30869069 Free article. Danish.

48

Neo-antigen specific memory T-cell responses in healthy individuals.

Holmström MO, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Oncoimmunology. 2019 Apr 19;8(7):1599640. doi: 10.1080/2162402X.2019.1599640. eCollection 2019. Oncoimmunology. 2019. PMID: 31143522 Free PMC article.

49

Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy.

Holmström MO, Novotny GW, Petersen J, Aaboe-Jørgensen M, Hasselbalch HC, Andersen MH, Nielsen SL, Fassi DE, Schöllkopf C. Holmström MO, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2019 Dec;60(13):3296-3299. doi: 10.1080/10428194.2019.1633634. Epub 2019 Jul 1. Leuk Lymphoma. 2019. PMID: 31256699 No abstract available.

50

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.

Sørensen AL, Bjørn ME, Riley CH, Holmstrøm M, Andersen MH, Svane IM, Mikkelsen SU, Skov V, Kjaer L, Hasselbalch HC, Nielsen CH. Sørensen AL, et al. Among authors: hasselbalch hc. Eur J Haematol. 2019 Oct;103(4):351-361. doi: 10.1111/ejh.13292. Epub 2019 Aug 18. Eur J Haematol. 2019. PMID: 31297883 Clinical Trial.

51

[Therapeutic cancer vaccination for treatment of haematological cancers].

Holmström MO, Grauslund JH, Dahlager-Jørgensen NG, Klausen U, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2019 Oct 14;181(20A):V04190233. Ugeskr Laeger. 2019. PMID: 31610839 Free article. Danish.

52

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.

Holmström MO, Cordua S, Skov V, Kjær L, Pallisgaard N, Ellervik C, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Cancer Immunol Immunother. 2020 Feb;69(2):315-324. doi: 10.1007/s00262-019-02473-y. Epub 2020 Jan 8. Cancer Immunol Immunother. 2020. PMID: 31915854 Free PMC article. Review.

53

Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.

Pedersen RK, Andersen M, Knudsen TA, Sajid Z, Gudmand-Hoeyer J, Dam MJB, Skov V, Kjaer L, Ellervik C, Larsen TS, Hansen D, Pallisgaard N, Hasselbalch HC, Ottesen JT. Pedersen RK, et al. Among authors: hasselbalch hc. Cancer Med. 2020 Mar;9(6):2039-2051. doi: 10.1002/cam4.2741. Epub 2020 Jan 28. Cancer Med. 2020. PMID: 31991066 Free PMC article.

54

[Myeloproliferative neoplasms and chronic inflammatory bowel disease].

Hesselø H, Bak M, Boysen T, Bytzer P, Hasselbalch HC. Hesselø H, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2020 May 5;182(22):V09190483. Ugeskr Laeger. 2020. PMID: 32515326 Free article. Review. Danish.

55

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms.

Holmström MO, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Cancers (Basel). 2020 Jul 2;12(7):1763. doi: 10.3390/cancers12071763. Cancers (Basel). 2020. PMID: 32630667 Free PMC article. Review.

56

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer's disease: evidences and perspectives.

Hasselbalch HC, Skov V, Kjær L, Sørensen TL, Ellervik C, Wienecke T. Hasselbalch HC, et al. J Neuroinflammation. 2020 Aug 23;17(1):248. doi: 10.1186/s12974-020-01877-3. J Neuroinflammation. 2020. PMID: 32829706 Free PMC article. Review.

57

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Sørensen AL, Mikkelsen SU, Knudsen TA, Bjørn ME, Andersen CL, Bjerrum OW, Brochmann N, Patel DA, Gjerdrum LMR, El Fassi D, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Ellervik C, Pallisgaard N, Thomassen M, Kjær L, Skov V, Hasselbalch HC. Sørensen AL, et al. Among authors: hasselbalch hc. Haematologica. 2020 Sep 1;105(9):2262-2272. doi: 10.3324/haematol.2019.235648. Haematologica. 2020. PMID: 33054051 Free PMC article. Clinical Trial.

58

Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: A retrospective cohort study.

Sørensen AL, Knudsen TA, Skov V, Kjaer L, Holm N, Ellervik C, Hasselbalch HC. Sørensen AL, et al. Among authors: hasselbalch hc. Br J Haematol. 2021 Apr;193(1):83-92. doi: 10.1111/bjh.17130. Epub 2020 Nov 10. Br J Haematol. 2021. PMID: 33169852

59

The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.

Hasselbalch HC, Elvers M, Schafer AI. Hasselbalch HC, et al. Blood. 2021 Apr 22;137(16):2152-2160. doi: 10.1182/blood.2020008109. Blood. 2021. PMID: 33649757 Free article. Review.

60

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms.

Handlos Grauslund J, Holmström MO, Jørgensen NG, Klausen U, Weis-Banke SE, El Fassi D, Schöllkopf C, Clausen MB, Gjerdrum LMR, Breinholt MF, Kjeldsen JW, Hansen M, Koschmieder S, Chatain N, Novotny GW, Petersen J, Kjær L, Skov V, Met Ö, Svane IM, Hasselbalch HC, Andersen MH. Handlos Grauslund J, et al. Among authors: hasselbalch hc. Front Oncol. 2021 Feb 26;11:637420. doi: 10.3389/fonc.2021.637420. eCollection 2021. Front Oncol. 2021. PMID: 33718228 Free PMC article.

61

Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Dam MJB, Pedersen RK, Knudsen TA, Andersen M, Skov V, Kjaer L, Hasselbalch HC, Ottesen JT. Dam MJB, et al. Among authors: hasselbalch hc. Eur J Haematol. 2021 Dec;107(6):624-633. doi: 10.1111/ejh.13700. Epub 2021 Sep 30. Eur J Haematol. 2021. PMID: 34411333 Clinical Trial.

62

[Elevated blood cell counts and vascular disease with the myeloproliferative neoplasms as model diseases].

Hasselbalch HC, Knudsen TA, Sørensen AL, Christensen SF, Larsen MK, Bak M, El Fassi D, Cordua S, Brabrand M, Thomsen G, Stentoft J, Starklint J, Ellervik C, Wienecke T, Bruun NE, Eickhardt-Dalbøge CE, Kjær L, Skov V. Hasselbalch HC, et al. Ugeskr Laeger. 2021 Oct 18;183(42):V03210282. Ugeskr Laeger. 2021. PMID: 34709157 Free article. Review. Danish.

63

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression.

Carnaz Simões AM, Holmström MO, Aehnlich P, Rahbech A, Radziwon-Balicka A, Zamora C, Wirenfeldt Klausen T, Skov V, Kjær L, Ellervik C, Fassi DE, Vidal S, Hasselbalch HC, Andersen MH, Thor Straten P. Carnaz Simões AM, et al. Among authors: hasselbalch hc. Front Immunol. 2022 May 6;13:866610. doi: 10.3389/fimmu.2022.866610. eCollection 2022. Front Immunol. 2022. PMID: 35603202 Free PMC article.

64

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.

Gigoux M, Holmström MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CC, Mangarin LMB, Redmond D, Verma S, Schad S, George MM, Venkatesh D, Ghosh A, Hoyos D, Molvi Z, Kamaz B, Marneth AE, Duke W, Leventhal MJ, Jan M, Ho VT, Hobbs GS, Knudsen TA, Skov V, Kjær L, Larsen TS, Hansen DL, Lindsley RC, Hasselbalch H, Grauslund JH, Lisle TL, Met Ö, Wilkinson P, Greenbaum B, Sepulveda MA, Chan T, Rampal R, Andersen MH, Abdel-Wahab O, Bhardwaj N, Wolchok JD, Mullally A, Merghoub T. Gigoux M, et al. Sci Transl Med. 2022 Jun 15;14(649):eaba4380. doi: 10.1126/scitranslmed.aba4380. Epub 2022 Jun 15. Sci Transl Med. 2022. PMID: 35704596 Free PMC article.

65

Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers.

Liisborg C, Skov V, Kjær L, Hasselbalch HC, Lykke Sørensen T. Liisborg C, et al. Among authors: hasselbalch hc. PLoS One. 2022 Jun 16;17(6):e0269960. doi: 10.1371/journal.pone.0269960. eCollection 2022. PLoS One. 2022. PMID: 35709177 Free PMC article.

66

Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.

Skov V, Thomassen M, Kjær L, Ellervik C, Larsen MK, Knudsen TA, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. PLoS One. 2022 Jun 30;17(6):e0270669. doi: 10.1371/journal.pone.0270669. eCollection 2022. PLoS One. 2022. PMID: 35771847 Free PMC article.

67

Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study.

Christensen SF, Svingel LS, Kjaersgaard A, Stenling A, Darvalics B, Paulsson B, Andersen CL, Christiansen CF, Stentoft J, Starklint J, Severinsen MT, Clausen MB, Hilsøe MH, Hasselbalch HC, Frederiksen H, Mikkelsen EM, Bak M. Christensen SF, et al. Among authors: hasselbalch hc. Eur J Haematol. 2022 Nov;109(5):526-541. doi: 10.1111/ejh.13841. Epub 2022 Aug 26. Eur J Haematol. 2022. PMID: 35900040 Free PMC article.

68

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression.

Simões AMC, Holmström MO, Aehnlich P, Rahbech A, Peeters MJW, Radziwon-Balicka A, Zamora C, Klausen TW, Skov V, Kjær L, Ellervik C, Fassi DE, Vidal S, Hasselbalch HC, Andersen MH, Straten PT. Simões AMC, et al. Among authors: hasselbalch hc. Front Immunol. 2022 Aug 5;13:970322. doi: 10.3389/fimmu.2022.970322. eCollection 2022. Front Immunol. 2022. PMID: 35990670 Free PMC article.

69

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives.

Hasselbalch H, Skov V, Kjær L, Larsen MK, Knudsen TA, Lucijanić M, Kusec R. Hasselbalch H, et al. Cancers (Basel). 2022 Nov 9;14(22):5495. doi: 10.3390/cancers14225495. Cancers (Basel). 2022. PMID: 36428587 Free PMC article.

70

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.

Hasselbalch HC, Junker P, Skov V, Kjær L, Knudsen TA, Larsen MK, Holmström MO, Andersen MH, Jensen C, Karsdal MA, Willumsen N. Hasselbalch HC, et al. Cancers (Basel). 2023 Aug 29;15(17):4323. doi: 10.3390/cancers15174323. Cancers (Basel). 2023. PMID: 37686599 Free PMC article. Review.

71

The CALR mutations enhance the expression of the immunosuppressive proteins GARP and LAP on peripheral blood lymphocytes through increased binding of activated platelets.

Holmström MO, Ruders JH, Riley CH, Larsen MK, Grauslund JH, Kjær L, Skov V, Ellervik C, Guo BB, Linden M, Hasselbalch HC, Andersen MH. Holmström MO, et al. Among authors: hasselbalch hc. Br J Haematol. 2024 Oct;205(4):1417-1429. doi: 10.1111/bjh.19711. Epub 2024 Aug 20. Br J Haematol. 2024. PMID: 39161981

72

A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.

Silver RT, Hasselbalch HC. Silver RT, et al. Among authors: hasselbalch hc. Leukemia. 2026 Apr 8. doi: 10.1038/s41375-026-02882-w. Online ahead of print. Leukemia. 2026. PMID: 41951941 Review.

73

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al. Michiels JJ, et al. Neth J Med. 1999 Feb;54(2):46-62. doi: 10.1016/s0300-2977(98)00143-0. Neth J Med. 1999. PMID: 10079679 Review.

74

Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.

Nielsen I, Hasselbalch HC. Nielsen I, et al. Among authors: hasselbalch hc. Am J Hematol. 2003 Sep;74(1):26-31. doi: 10.1002/ajh.10375. Am J Hematol. 2003. PMID: 12949887 Free article.

75

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

Hasselbalch HC, Bjerrum OW, Jensen BA, Clausen NT, Hansen PB, Birgens H, Therkildsen MH, Ralfkiaer E. Hasselbalch HC, et al. Am J Hematol. 2003 Dec;74(4):238-42. doi: 10.1002/ajh.10431. Am J Hematol. 2003. PMID: 14635203 Free article. Clinical Trial.

76

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G; Nordic Study Group for Myeloproliferative Disorders. Samuelsson J, et al. Cancer. 2006 Jun 1;106(11):2397-405. doi: 10.1002/cncr.21900. Cancer. 2006. PMID: 16639737 Free article. Clinical Trial.

77

The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders.

Hasselbalch HC, Riley CH. Hasselbalch HC, et al. Curr Drug Targets. 2007 Feb;8(2):247-56. doi: 10.2174/138945007779940133. Curr Drug Targets. 2007. PMID: 17305502 Review.

78

Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2012 Jan;53(1):123-9. doi: 10.3109/10428194.2011.597905. Epub 2011 Aug 1. Leuk Lymphoma. 2012. PMID: 21806350

79

Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.

Andersen CL, Hasselbalch H, Grønbæk K. Andersen CL, et al. Leuk Res. 2012 Apr;36(4):485-7. doi: 10.1016/j.leukres.2011.11.018. Epub 2011 Dec 15. Leuk Res. 2012. PMID: 22177454

80

Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance.

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. Leuk Res. 2012 Nov;36(11):1387-92. doi: 10.1016/j.leukres.2012.07.009. Epub 2012 Aug 9. Leuk Res. 2012. PMID: 22877729

81

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.

Silver RT, Kiladjian JJ, Hasselbalch HC. Silver RT, et al. Among authors: hasselbalch hc. Expert Rev Hematol. 2013 Feb;6(1):49-58. doi: 10.1586/ehm.12.69. Expert Rev Hematol. 2013. PMID: 23373780

82

The role of cytokines in the initiation and progression of myelofibrosis.

Hasselbalch HC. Hasselbalch HC. Cytokine Growth Factor Rev. 2013 Apr;24(2):133-45. doi: 10.1016/j.cytogfr.2013.01.004. Epub 2013 Feb 13. Cytokine Growth Factor Rev. 2013. PMID: 23415024 Review.

83

A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?

Hasselbalch HC. Hasselbalch HC. Leuk Res. 2014 Feb;38(2):263-6. doi: 10.1016/j.leukres.2013.07.002. Epub 2013 Aug 9. Leuk Res. 2014. PMID: 23932394

84

Myeloproliferative neoplasms in five multiple sclerosis patients.

Thorsteinsdottir S, Bjerrum OW, Hasselbalch HC. Thorsteinsdottir S, et al. Among authors: hasselbalch hc. Leuk Res Rep. 2013 Jul 31;2(2):61-3. doi: 10.1016/j.lrr.2013.06.004. eCollection 2013. Leuk Res Rep. 2013. PMID: 24371783 Free PMC article.

85

A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.

Andersen CL, Mortensen NB, Klausen TW, Vestergaard H, Bjerrum OW, Hasselbalch HC. Andersen CL, et al. Among authors: hasselbalch hc. Haematologica. 2014 Jan;99(1):e5-7. doi: 10.3324/haematol.2013.096669. Haematologica. 2014. PMID: 24425692 Free PMC article. Clinical Trial. No abstract available.

86

Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation.

Hasselbalch HC, Skov V, Stauffer Larsen T, Thomassen M, Hasselbalch Riley C, Jensen MK, Bjerrum OW, Kruse TA. Hasselbalch HC, et al. Among authors: hasselbalch riley c. PLoS One. 2014 Jan 13;9(1):e85567. doi: 10.1371/journal.pone.0085567. eCollection 2014. PLoS One. 2014. PMID: 24454890 Free PMC article.

87

Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms.

Christensen AS, Møller JB, Hasselbalch HC. Christensen AS, et al. Among authors: hasselbalch hc. Leuk Res. 2014 Apr;38(4):490-5. doi: 10.1016/j.leukres.2014.01.014. Epub 2014 Feb 4. Leuk Res. 2014. PMID: 24630365

88

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.

Andersen CL, Bjørn ME, McMullin MF, Harrison C, Samuelsson J, Ejerblad E, Zweegman S, Fernandes S, Bareford D, Knapper S, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Skov V, Thomassen M, Kruse T, Grønbæk K, Hasselbalch HC. Andersen CL, et al. Among authors: hasselbalch hc. Leuk Res. 2014 Jul;38(7):816-21. doi: 10.1016/j.leukres.2014.04.002. Epub 2014 Apr 14. Leuk Res. 2014. PMID: 24836761 Clinical Trial.

89

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera.

Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Leuk Res Rep. 2014 Aug 1;3(2):73-5. doi: 10.1016/j.lrr.2014.05.003. eCollection 2014. Leuk Res Rep. 2014. PMID: 25379406 Free PMC article.

90

Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression.

Hasselbalch HC, Thomassen M, Riley CH, Kjær L, Larsen TS, Jensen MK, Bjerrum OW, Kruse TA, Skov V. Hasselbalch HC, et al. PLoS One. 2014 Nov 14;9(11):e112786. doi: 10.1371/journal.pone.0112786. eCollection 2014. PLoS One. 2014. PMID: 25397683 Free PMC article.

91

The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.

Bjørn ME, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Clin Case Rep. 2015 Jun;3(6):499-503. doi: 10.1002/ccr3.281. Epub 2015 May 4. Clin Case Rep. 2015. PMID: 26185657 Free PMC article.

92

WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect--the Danish experience.

Madelung AB, Bondo H, Stamp I, Løvgreen P, Nielsen SL, Falensteen A, Knudsen H, Svendsen KD, Lange T, Ralfkiaer E, Nielsen K, Hasselbalch H, Thiele J. Madelung AB, et al. APMIS. 2015 Sep;123(9):787-92. doi: 10.1111/apm.12417. Epub 2015 Jul 22. APMIS. 2015. PMID: 26200697

93

Smoking and philadelphia-negative chronic myeloproliferative neoplasms.

Lindholm Sørensen A, Hasselbalch HC. Lindholm Sørensen A, et al. Among authors: hasselbalch hc. Eur J Haematol. 2016 Jul;97(1):63-9. doi: 10.1111/ejh.12684. Epub 2015 Oct 13. Eur J Haematol. 2016. PMID: 26384085

94

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.

Hasselbalch HC, Bjørn ME. Hasselbalch HC, et al. Mediators Inflamm. 2015;2015:102476. doi: 10.1155/2015/102476. Epub 2015 Oct 28. Mediators Inflamm. 2015. PMID: 26604428 Free PMC article. Review.

95

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art.

Hermouet S, Hasselbalch HC, Čokić V. Hermouet S, et al. Among authors: hasselbalch hc. Mediators Inflamm. 2015;2015:964613. doi: 10.1155/2015/964613. Epub 2015 Nov 23. Mediators Inflamm. 2015. PMID: 26681841 Free PMC article. No abstract available.

96

Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study.

Frederiksen H, Farkas DK, Christiansen CF, Larsen TS, Hasselbalch HC, Stentoft J, Sørensen HT. Frederiksen H, et al. Among authors: hasselbalch hc. Lancet Haematol. 2015 Jul;2(7):e289-96. doi: 10.1016/S2352-3026(15)00092-7. Epub 2015 Jun 11. Lancet Haematol. 2015. PMID: 26688384

97

Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms.

Sørensen AL, Hasselbalch HC. Sørensen AL, et al. Among authors: hasselbalch hc. Leuk Res. 2016 Feb;41:27-35. doi: 10.1016/j.leukres.2015.11.017. Epub 2015 Dec 2. Leuk Res. 2016. PMID: 26718091

98

A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate.

Sørensen AL, Kallenbach K, Hasselbalch HC. Sørensen AL, et al. Among authors: hasselbalch hc. Leuk Res Rep. 2016 Jun 27;6:20-3. doi: 10.1016/j.lrr.2016.06.004. eCollection 2016. Leuk Res Rep. 2016. PMID: 27489765 Free PMC article.

99

Molecular profiling as a novel tool to predict response to interferon-α2 in MPNs: The proof of concept in early myelofibrosis.

Hasselbalch HC. Hasselbalch HC. Cancer. 2017 Jul 15;123(14):2600-2603. doi: 10.1002/cncr.30676. Epub 2017 May 18. Cancer. 2017. PMID: 28518284 Free article. No abstract available.

100

Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.

Bak M, Sørensen TL, Flachs EM, Zwisler AD, Juel K, Frederiksen H, Hasselbalch HC. Bak M, et al. Among authors: hasselbalch hc. JAMA Ophthalmol. 2017 Aug 1;135(8):835-843. doi: 10.1001/jamaophthalmol.2017.2011. JAMA Ophthalmol. 2017. PMID: 28655032 Free PMC article.

101

Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.

Herborg LL, Nederby L, Hasselbalch HC, Aggerholm A, Roug AS. Herborg LL, et al. Among authors: hasselbalch hc. Int J Lab Hematol. 2018 Jun;40(3):320-325. doi: 10.1111/ijlh.12787. Epub 2018 Feb 10. Int J Lab Hematol. 2018. PMID: 29427319

102

Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms.

Tolstrup Larsen R, Tang LH, Brochmann N, Meulengracht Flachs E, Illemann Christensen A, Hasselbalch HC, Zwisler AD. Tolstrup Larsen R, et al. Among authors: hasselbalch hc. Eur J Haematol. 2018 Jun;100(6):550-559. doi: 10.1111/ejh.13048. Epub 2018 Apr 6. Eur J Haematol. 2018. PMID: 29464777

103

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Barbui T, et al. Among authors: hasselbalch hc. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Leukemia. 2018. PMID: 29515238 Free PMC article. Review.

104

The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms-An explorative study.

Pedersen KM, Zangger G, Brochmann N, Grønfeldt BM, Zwisler AD, Hasselbalch HC, Tang LH. Pedersen KM, et al. Among authors: hasselbalch hc. Eur J Cancer Care (Engl). 2018 Sep;27(5):e12865. doi: 10.1111/ecc.12865. Epub 2018 Jun 11. Eur J Cancer Care (Engl). 2018. PMID: 29888803

105

Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study.

Pedersen KM, Bak M, Sørensen AL, Zwisler AD, Ellervik C, Larsen MK, Hasselbalch HC, Tolstrup JS. Pedersen KM, et al. Among authors: hasselbalch hc. Cancer Med. 2018 Nov;7(11):5796-5802. doi: 10.1002/cam4.1815. Epub 2018 Oct 14. Cancer Med. 2018. PMID: 30318865 Free PMC article.

106

Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis.

Bjørn ME, Brimnes MK, Gudbrandsdottir S, Andersen CL, Poulsen HE, Henriksen T, Hasselbalch HC, Nielsen CH. Bjørn ME, et al. Among authors: hasselbalch hc. Leuk Lymphoma. 2019 Oct;60(10):2549-2557. doi: 10.1080/10428194.2019.1579323. Epub 2019 Feb 20. Leuk Lymphoma. 2019. PMID: 30785365

107

Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat.

McPherson S, Greenfield G, Andersen C, Grinfeld J, Hasselbalch HC, Nangalia J, Mills KI, McMullin MF. McPherson S, et al. Among authors: hasselbalch hc. Exp Hematol. 2019 Nov;79:26-34. doi: 10.1016/j.exphem.2019.09.025. Epub 2019 Sep 26. Exp Hematol. 2019. PMID: 31563618 Free article. Clinical Trial.

108

The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera.

Nersesjan V, Zervides KA, Sørensen AL, Kjaer L, Skov V, Hasselbalch HC. Nersesjan V, et al. Among authors: hasselbalch hc. Eur J Haematol. 2020 Jan;104(1):46-54. doi: 10.1111/ejh.13334. Epub 2019 Nov 22. Eur J Haematol. 2020. PMID: 31584701

109

Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

Hasselbalch HC. Hasselbalch HC. Haematologica. 2019 Nov;104(11):2119-2125. doi: 10.3324/haematol.2019.229039. Haematologica. 2019. PMID: 31666340 Free PMC article. No abstract available.

110

Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms - Impact Of Comorbidity.

Frederiksen H, Szépligeti S, Bak M, Ghanima W, Hasselbalch HC, Christiansen CF. Frederiksen H, et al. Among authors: hasselbalch hc. Clin Epidemiol. 2019 Nov 1;11:955-967. doi: 10.2147/CLEP.S216787. eCollection 2019. Clin Epidemiol. 2019. PMID: 31807079 Free PMC article.

111

Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people.

Jayasuriya NA, Kjaergaard AD, Pedersen KM, Sørensen AL, Bak M, Larsen MK, Nordestgaard BG, Bojesen SE, Çolak Y, Skov V, Kjaer L, Tolstrup JS, Hasselbalch HC, Ellervik C. Jayasuriya NA, et al. Among authors: hasselbalch hc. Br J Haematol. 2020 Apr;189(2):323-334. doi: 10.1111/bjh.16321. Epub 2019 Dec 25. Br J Haematol. 2020. PMID: 31875952 Free article.

112

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms.

Liisborg C, Hasselbalch HC, Sørensen TL. Liisborg C, et al. Among authors: hasselbalch hc. Cancers (Basel). 2020 Mar 2;12(3):573. doi: 10.3390/cancers12030573. Cancers (Basel). 2020. PMID: 32121664 Free PMC article. Review.

113

[Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].

Hasselbalch HC, Poulsen A, Skov V, Kjær L, Nielsen CH, Poulsen TD. Hasselbalch HC, et al. Ugeskr Laeger. 2020 Jun 15;182(25):V04200234. Ugeskr Laeger. 2020. PMID: 32584762 Free article. Review. Danish.

114

Early detection of myeloproliferative neoplasms in a Danish general population study.

Cordua S, Kjaer L, Skov V, Pallisgaard N, Kefala M, Gjerdrum LMR, Hasselbalch HC, Ellervik C. Cordua S, et al. Among authors: hasselbalch hc. Leukemia. 2021 Sep;35(9):2706-2709. doi: 10.1038/s41375-021-01159-8. Epub 2021 Feb 15. Leukemia. 2021. PMID: 33589756 No abstract available.

115

COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.

Hasselbalch HC, Skov V, Kjær L, Ellervik C, Poulsen A, Poulsen TD, Nielsen CH. Hasselbalch HC, et al. Cytokine Growth Factor Rev. 2021 Aug;60:28-45. doi: 10.1016/j.cytogfr.2021.03.006. Epub 2021 Apr 14. Cytokine Growth Factor Rev. 2021. PMID: 33992887 Free PMC article. Review.

116

Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care.

Christensen SF, Scherber RM, Mazza GL, Dueck AC, Brochmann N, Andersen CL, Hasselbalch HC, Mesa RA, Geyer HL. Christensen SF, et al. Among authors: hasselbalch hc. BMC Cancer. 2021 Jun 10;21(1):691. doi: 10.1186/s12885-021-08439-7. BMC Cancer. 2021. PMID: 34112113 Free PMC article.

117

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.

Knudsen TA, Skov V, Stevenson K, Werner L, Duke W, Laurore C, Gibson CJ, Nag A, Thorner AR, Wollison B, Hansen DL, Ellervik C, El Fassi D, de Stricker K, Ocias LF, Brabrand M, Bjerrum OW, Overgaard UM, Frederiksen M, Kristensen TK, Kruse TA, Thomassen M, Mourits-Andersen T, Severinsen MT, Stentoft J, Starklint J, Neuberg DS, Kjaer L, Larsen TS, Hasselbalch HC, Lindsley RC, Mullally A. Knudsen TA, et al. Among authors: hasselbalch hc. Blood Adv. 2022 Apr 12;6(7):2107-2119. doi: 10.1182/bloodadvances.2021004856. Blood Adv. 2022. PMID: 34507355 Free PMC article. Clinical Trial.

118

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms.

Hasselbalch HC, Silver RT. Hasselbalch HC, et al. Hemasphere. 2021 Nov 18;5(12):e645. doi: 10.1097/HS9.0000000000000645. eCollection 2021 Dec. Hemasphere. 2021. PMID: 34805764 Free PMC article. No abstract available.

119

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Gisslinger H; PROUD-PV Study Group. Kiladjian JJ, et al. Among authors: hasselbalch hc. Leukemia. 2022 May;36(5):1408-1411. doi: 10.1038/s41375-022-01528-x. Epub 2022 Feb 24. Leukemia. 2022. PMID: 35210530 Free PMC article. No abstract available.

120

Coronary artery- and aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms.

Solli CN, Chamat-Hedemand S, Elming H, Ngo A, Kjær L, Skov V, Sørensen AL, Ellervik C, Fuchs A, Sigvardsen PE, Kühl JT, Kofoed KF, Nordestgaard BG, Hasselbalch H, Bruun NE. Solli CN, et al. Int J Cardiol. 2022 Oct 1;364:112-118. doi: 10.1016/j.ijcard.2022.06.029. Epub 2022 Jun 16. Int J Cardiol. 2022. PMID: 35716942 Free article.

121

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment.

Eickhardt-Dalbøge CS, Ingham AC, Andersen LO, Nielsen HV, Fuursted K, Stensvold CR, Larsen MK, Kjær L, Christensen SF, Knudsen TA, Skov V, Ellervik C, Olsen LR, Hasselbalch HC, Nielsen XC, Christensen JJE. Eickhardt-Dalbøge CS, et al. Among authors: hasselbalch hc. Blood Adv. 2023 Jul 11;7(13):3326-3337. doi: 10.1182/bloodadvances.2022008555. Blood Adv. 2023. PMID: 36260736 Free PMC article.

122

Interferon alpha-2 treatment reduces circulating neutrophil extracellular trap levels in myeloproliferative neoplasms.

Massarenti L, Knudsen TA, Enevold C, Skov V, Kjaer L, Larsen MK, Larsen TS, Hansen DL, Hasselbalch HC, Nielsen CH. Massarenti L, et al. Among authors: hasselbalch hc. Br J Haematol. 2023 Jul;202(2):318-327. doi: 10.1111/bjh.18845. Epub 2023 May 22. Br J Haematol. 2023. PMID: 37211985

123

Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms.

Skov V, Thomassen M, Kjaer L, Larsen MK, Knudsen TA, Ellervik C, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. Eur J Haematol. 2023 Nov;111(5):805-814. doi: 10.1111/ejh.14081. Epub 2023 Aug 28. Eur J Haematol. 2023. PMID: 37640394

124

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.

Sørensen AL, Skov V, Kjær L, Bjørn ME, Eickhardt-Dalbøge CS, Larsen MK, Nielsen CH, Thomsen C, Rahbek Gjerdrum LM, Knudsen TA, Ellervik C, Overgaard UM, Andersen CL, Hasselbalch H. Sørensen AL, et al. Blood Adv. 2024 Oct 22;8(20):5416-5425. doi: 10.1182/bloodadvances.2024013170. Blood Adv. 2024. PMID: 39163611 Free PMC article. Clinical Trial.

125

Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms.

Davidsen ID, Larsen MK, Löffler L, Skov V, Kjær L, Knudsen TA, Sørensen AL, Christensen SF, Cordua S, Eickhardt-Dalbøge CS, Kristiansen MH, Ellervik C, Wienecke T, Hasselbalch HC. Davidsen ID, et al. Among authors: hasselbalch hc. Blood Adv. 2025 Dec 9;9(23):6189-6198. doi: 10.1182/bloodadvances.2025017016. Blood Adv. 2025. PMID: 40966426 Free PMC article.

126

Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin.

Hasselbalch HC, Clausen NT, Jensen BA. Hasselbalch HC, et al. Am J Hematol. 2002 Jun;70(2):92-9. doi: 10.1002/ajh.10076. Am J Hematol. 2002. PMID: 12111781 Free article. Clinical Trial.

127

Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.

Penninga E, Jensen BA, Hansen PB, Clausen NT, Mourits-Andersen T, Nielsen OJ, Hasselbalch HC. Penninga E, et al. Among authors: hasselbalch hc. Clin Lab Haematol. 2004 Oct;26(5):335-40. doi: 10.1111/j.1365-2257.2004.00637.x. Clin Lab Haematol. 2004. PMID: 15485463 Clinical Trial.

128

Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?

Hasselbalch HC. Hasselbalch HC. Leuk Res. 2009 Jan;33(1):11-8. doi: 10.1016/j.leukres.2008.06.002. Epub 2008 Jul 15. Leuk Res. 2009. PMID: 18632152 Review.

129

Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.

Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sørensen HT. Frederiksen H, et al. Among authors: hasselbalch hc. Blood. 2011 Dec 15;118(25):6515-20. doi: 10.1182/blood-2011-04-348755. Epub 2011 Oct 28. Blood. 2011. PMID: 22039256 Free article.

130

High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms.

Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J, Girodon F, Andréasson B. Enblom A, et al. Eur J Intern Med. 2015 Jun;26(5):344-7. doi: 10.1016/j.ejim.2015.03.009. Epub 2015 Apr 8. Eur J Intern Med. 2015. PMID: 25863408

131

Statin treatment, oxidative stress and inflammation in a Danish population.

Sørensen AL, Hasselbalch HC, Nielsen CH, Poulsen HE, Ellervik C. Sørensen AL, et al. Among authors: hasselbalch hc. Redox Biol. 2019 Feb;21:101088. doi: 10.1016/j.redox.2018.101088. Epub 2018 Dec 21. Redox Biol. 2019. PMID: 30594900 Free PMC article.

132

Bridging blood cancers and inflammation: The reduced Cancitis model.

Ottesen JT, Pedersen RK, Sajid Z, Gudmand-Hoeyer J, Bangsgaard KO, Skov V, Kjær L, Knudsen TA, Pallisgaard N, Hasselbalch HC, Andersen M. Ottesen JT, et al. Among authors: hasselbalch hc. J Theor Biol. 2019 Mar 21;465:90-108. doi: 10.1016/j.jtbi.2019.01.001. Epub 2019 Jan 4. J Theor Biol. 2019. PMID: 30615883

133

Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration.

Liisborg C, Nielsen MK, Hasselbalch HC, Sørensen TL. Liisborg C, et al. Among authors: hasselbalch hc. EClinicalMedicine. 2020 Sep 9;26:100526. doi: 10.1016/j.eclinm.2020.100526. eCollection 2020 Sep. EClinicalMedicine. 2020. PMID: 33089124 Free PMC article.

134

Dynamics of competing heterogeneous clones in blood cancers explains multiple observations - a mathematical modeling approach.

Bangsgaard KO, Andersen M, Skov V, Kjær L, Hasselbalch HC, Ottesen JT. Bangsgaard KO, et al. Among authors: hasselbalch hc. Math Biosci Eng. 2020 Nov 4;17(6):7645-7670. doi: 10.3934/mbe.2020389. Math Biosci Eng. 2020. PMID: 33378913 Free article.

135

Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study.

Sørensen AL, Hasselbalch HC, Bjørn ME, Nielsen CH, Cordua S, Skov V, Kjær L, Poulsen HE, Ellervik C. Sørensen AL, et al. Among authors: hasselbalch hc. Redox Biol. 2021 May;41:101895. doi: 10.1016/j.redox.2021.101895. Epub 2021 Feb 13. Redox Biol. 2021. PMID: 33621788 Free PMC article.

136

Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus.

Frankel AE, Yip WC, Naik E, Hasselbalch HC. Frankel AE, et al. Among authors: hasselbalch hc. Clin Case Rep. 2021 Jun 9;9(6):e04218. doi: 10.1002/ccr3.4218. eCollection 2021 Jun. Clin Case Rep. 2021. PMID: 34136234 Free PMC article.

137

Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study.

Tuyet Kristensen D, Kisbye Øvlisen A, Hjort Kyneb Jakobsen L, Tang Severinsen M, Hannig LH, Starklint J, Hagemann Hilsøe M, Pommer Vallentin A, Brabrand M, Hasselbalch HC, El-Galaly TC, Stidsholt Roug A. Tuyet Kristensen D, et al. Among authors: hasselbalch hc. Blood Adv. 2023 Jul 25;7(14):3450-3457. doi: 10.1182/bloodadvances.2023009784. Blood Adv. 2023. PMID: 36877642 Free PMC article.

138

High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms.

Solli CN, Chamat-Hedemand S, Elming H, Ngo A, Kjaer L, Skov V, Sørensen AL, Ellervik C, Hasselbalch H, Bruun NE. Solli CN, et al. Eur J Haematol. 2023 Sep;111(3):400-406. doi: 10.1111/ejh.14019. Epub 2023 Jun 7. Eur J Haematol. 2023. PMID: 37286366

139

Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.

Hasselbalch HC, Skov V, Kjaer L, Larsen MK. Hasselbalch HC, et al. Br J Haematol. 2024 Jan;204(1):16-18. doi: 10.1111/bjh.19173. Epub 2023 Nov 13. Br J Haematol. 2024. PMID: 37957927

140

JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.

Eickhardt-Dalbøge CS, Nielsen HV, Fuursted K, Stensvold CR, Andersen LOB, Lilje B, Larsen MK, Kjær L, Christensen SF, Knudsen TA, Skov V, Sørensen AL, Ellervik C, Olsen LR, Christensen JJE, Nielsen XC, Hasselbalch HC, Ingham AC. Eickhardt-Dalbøge CS, et al. Among authors: hasselbalch hc. Eur J Haematol. 2024 May;112(5):776-787. doi: 10.1111/ejh.14169. Epub 2024 Jan 16. Eur J Haematol. 2024. PMID: 38226781

141

Myeloproliferative Neoplasms and Dementia Risk: A Population-Based Cohort Study.

Sun Y, Veres K, Hasselbalch HC, Frederiksen H, Østgård LSG, Horváth-Puhó E, Henderson VW, Sørensen HT. Sun Y, et al. Among authors: hasselbalch hc. Eur J Haematol. 2025 Jan;114(1):45-56. doi: 10.1111/ejh.14297. Epub 2024 Sep 16. Eur J Haematol. 2025. PMID: 39279726 Free PMC article.

142

High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders.

Faurschou M, Nielsen OJ, Jensen MK, Hasselbalch HC. Faurschou M, et al. Among authors: hasselbalch hc. Am J Hematol. 2000 Oct;65(2):136-40. doi: 10.1002/1096-8652(200010)65:2<136::aid-ajh8>3.0.co;2-6. Am J Hematol. 2000. PMID: 10996831 Free article.

143

SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis.

Hasselbalch HC. Hasselbalch HC. Med Hypotheses. 2003 Aug;61(2):244-7. doi: 10.1016/s0306-9877(03)00155-5. Med Hypotheses. 2003. PMID: 12888313

144

A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.

Larsen TS, Hasselbalch HC, Pallisgaard N, Kerndrup GB. Larsen TS, et al. Among authors: hasselbalch hc. Cancer Genet Cytogenet. 2007 Jan 15;172(2):107-12. doi: 10.1016/j.cancergencyto.2006.09.015. Cancer Genet Cytogenet. 2007. PMID: 17213018

145

[Tyrosine kinase inhibitors in the treatment of polycythemia vera and related conditions. Danish Society of Hematology].

Larsen TS, Hasselbalch HC; Dansk Haematologisk Selskab. Larsen TS, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2008 Mar 17;170(12):1031. Ugeskr Laeger. 2008. PMID: 18397649 Danish. No abstract available.

146

Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.

Larsen TS, Pallisgaard N, de Stricker K, Møller MB, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Hematology. 2009 Feb;14(1):11-5. doi: 10.1179/102453309X385188. Hematology. 2009. PMID: 19154659 Free article.

147

Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.

Spivak JL, Hasselbalch H. Spivak JL, et al. Expert Rev Anticancer Ther. 2011 Mar;11(3):403-14. doi: 10.1586/era.11.10. Expert Rev Anticancer Ther. 2011. PMID: 21417854 Review.

148

High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis.

Hasselbalch HC, Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA. Hasselbalch HC, et al. Leuk Res. 2011 Oct;35(10):1330-4. doi: 10.1016/j.leukres.2011.03.013. Epub 2011 Apr 5. Leuk Res. 2011. PMID: 21470677

149

A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden.

Kjær L, Westman M, Hasselbalch Riley C, Høgdall E, Weis Bjerrum O, Hasselbalch H. Kjær L, et al. PLoS One. 2012;7(3):e33100. doi: 10.1371/journal.pone.0033100. Epub 2012 Mar 5. PLoS One. 2012. PMID: 22403733 Free PMC article.

150

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.

Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, Klausen TW, Larsen H, Mourits-Andersen HT, Nielsen CH, Nielsen OJ, Plesner T, Pulczynski S, Rasmussen IH, Rønnov-Jessen D, Hasselbalch HC. Gudbrandsdottir S, et al. Among authors: hasselbalch hc. Blood. 2013 Mar 14;121(11):1976-81. doi: 10.1182/blood-2012-09-455691. Epub 2013 Jan 4. Blood. 2013. PMID: 23293082 Free article. Clinical Trial.

151

World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience.

Madelung AB, Bondo H, Stamp I, Loevgreen P, Nielsen SL, Falensteen A, Knudsen H, Ehinger M, Dahl-Sørensen R, Mortensen NB, Svendsen KD, Lange T, Ralfkiaer E, Nielsen K, Hasselbalch HC, Thiele J. Madelung AB, et al. Among authors: hasselbalch hc. Am J Hematol. 2013 Dec;88(12):1012-6. doi: 10.1002/ajh.23554. Epub 2013 Sep 30. Am J Hematol. 2013. PMID: 23897670 Free article.

152

A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.

Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Rønnov-Jessen D, Vestergaard H, Klausen TW, Schöllkopf C. Birgens H, et al. Among authors: hasselbalch hc. Br J Haematol. 2013 Nov;163(3):393-9. doi: 10.1111/bjh.12541. Epub 2013 Aug 24. Br J Haematol. 2013. PMID: 23981017 Clinical Trial.

153

Corrigendum to "Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera" [Leuk. Res. Rep. 3 (2) (2014) 73-75].

Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC. Bjørn ME, et al. Among authors: hasselbalch hc. Leuk Res Rep. 2015 May 15;4(1):31. doi: 10.1016/j.lrr.2015.04.003. eCollection 2015. Leuk Res Rep. 2015. PMID: 26101742 Free PMC article.

154

The Danish National Chronic Myeloid Neoplasia Registry.

Bak M, Ibfelt EH, Stauffer Larsen T, Rønnov-Jessen D, Pallisgaard N, Madelung A, Udby L, Hasselbalch HC, Bjerrum OW, Andersen CL. Bak M, et al. Among authors: hasselbalch hc. Clin Epidemiol. 2016 Oct 25;8:567-572. doi: 10.2147/CLEP.S99462. eCollection 2016. Clin Epidemiol. 2016. PMID: 27822101 Free PMC article. Review.

155

A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.

Brochmann N, Flachs EM, Christensen AI, Andersen CL, Juel K, Hasselbalch HC, Zwisler AD. Brochmann N, et al. Among authors: hasselbalch hc. Clin Epidemiol. 2017 Mar 2;9:141-150. doi: 10.2147/CLEP.S117587. eCollection 2017. Clin Epidemiol. 2017. PMID: 28280390 Free PMC article.

156

Whole Blood Gene Expression Profiling in patients undergoing colon cancer surgery identifies differential expression of genes involved in immune surveillance, inflammation and carcinogenesis.

Watt SK, Hasselbalch HC, Skov V, Kjær L, Thomassen M, Kruse TA, Burton M, Gögenur I. Watt SK, et al. Among authors: hasselbalch hc. Surg Oncol. 2018 Jun;27(2):208-215. doi: 10.1016/j.suronc.2018.03.002. Epub 2018 Mar 27. Surg Oncol. 2018. PMID: 29937173

157

Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark.

Brochmann N, Flachs EM, Christensen AI, Bak M, Andersen CL, Juel K, Hasselbalch HC, Zwisler AD, Rottmann N. Brochmann N, et al. Among authors: hasselbalch hc. Clin Epidemiol. 2018 Dec 18;11:23-33. doi: 10.2147/CLEP.S162688. eCollection 2019. Clin Epidemiol. 2018. PMID: 30588121 Free PMC article.

158

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population.

Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C. Cordua S, et al. Among authors: hasselbalch hc. Blood. 2019 Aug 1;134(5):469-479. doi: 10.1182/blood.2019001113. Epub 2019 Jun 19. Blood. 2019. PMID: 31217187 Free article.

159

Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study.

Pedersen KM, Çolak Y, Ellervik C, Hasselbalch HC, Bojesen SE, Nordestgaard BG. Pedersen KM, et al. Among authors: hasselbalch hc. EClinicalMedicine. 2020 Feb 19;21:100280. doi: 10.1016/j.eclinm.2020.100280. eCollection 2020 Apr. EClinicalMedicine. 2020. PMID: 32382712 Free PMC article.

160

Global dynamics of healthy and cancer cells competing in the hematopoietic system.

Andersen M, Hasselbalch HC, Kjær L, Skov V, Ottesen JT. Andersen M, et al. Among authors: hasselbalch hc. Math Biosci. 2020 Aug;326:108372. doi: 10.1016/j.mbs.2020.108372. Epub 2020 May 19. Math Biosci. 2020. PMID: 32442449

161

Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib.

Frankel AE, Reddy R, DeSuza KR, Deeb K, Carlin AF, Smith D, Xie Y, Naik E, Silver RT, Hasselbalch HC. Frankel AE, et al. Among authors: hasselbalch hc. Clin Case Rep. 2021 Mar 7;9(4):2228-2235. doi: 10.1002/ccr3.3997. eCollection 2021 Apr. Clin Case Rep. 2021. PMID: 33936671 Free PMC article.

162

Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system.

Liisborg C, Skov V, Kjær L, Hasselbalch HC, Sørensen TL. Liisborg C, et al. Among authors: hasselbalch hc. Aging (Albany NY). 2021 Dec 26;13(24):25763-25777. doi: 10.18632/aging.203803. Epub 2021 Dec 26. Aging (Albany NY). 2021. PMID: 34954692 Free PMC article.

163

A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2.

Dam MJB, Pedersen RK, Knudsen TA, Andersen M, Ellervik C, Larsen MK, Kjaer L, Skov V, Hasselbalch HC, Ottesen JT. Dam MJB, et al. Among authors: hasselbalch hc. Cancer Med. 2023 Feb;12(4):4218-4226. doi: 10.1002/cam4.5285. Epub 2022 Oct 17. Cancer Med. 2023. PMID: 36254099 Free PMC article.

164

Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.

Larsen MK, Skov V, Kjær L, Eickhardt-Dalbøge CS, Knudsen TA, Kristiansen MH, Sørensen AL, Wienecke T, Andersen M, Ottesen JT, Gudmand-Høyer J, Snyder JA, Andersen MP, Torp-Pedersen C, Poulsen HE, Stiehl T, Hasselbalch HC, Ellervik C. Larsen MK, et al. Among authors: hasselbalch hc. Blood Cancer J. 2024 Feb 9;14(1):28. doi: 10.1038/s41408-024-00994-z. Blood Cancer J. 2024. PMID: 38331919 Free PMC article.

165

Prevalence and impact of additional CHIP mutations in JAK2V617F-positive ischaemic cerebrovascular patients.

Kristiansen MH, Skov V, Larsen MK, Kjær L, Nielsen CH, Hasselbalch HC, Wienecke T. Kristiansen MH, et al. Among authors: hasselbalch hc. Br J Haematol. 2025 Sep;207(3):1029-1037. doi: 10.1111/bjh.20242. Epub 2025 Jul 23. Br J Haematol. 2025. PMID: 40701821 Free PMC article.

166

Atrial Fibrillation in Philadelphia Chromosome-negative Myeloproliferative Neoplasms: Thromboinflammatory Crosstalk with a Focus on the NLRP3 Inflammasome.

Demska O, Szandruk-Bender M, Bruun NE, Skov V, Kjær L, Larsen MK, Ellervik C, Szmit S, Hasselbalch HC, Sobas M. Demska O, et al. Among authors: hasselbalch hc. Thromb Haemost. 2025 Dec 23. doi: 10.1055/a-2767-0451. Online ahead of print. Thromb Haemost. 2025. PMID: 41435879

167

Prime Time for The Use of Statins in MPNs: From Comorbidity Drugs to Disease-Modifying Partners.

Hasselbalch HC Sr. Hasselbalch HC Sr. Blood Adv. 2026 Feb 26:bloodadvances.2026019625. doi: 10.1182/bloodadvances.2026019625. Online ahead of print. Blood Adv. 2026. PMID: 41747195

168

Idiopathic myelofibrosis--an update with particular reference to clinical aspects and prognosis.

Hasselbalch HC. Hasselbalch HC. Int J Clin Lab Res. 1993;23(3):124-38. doi: 10.1007/BF02592297. Int J Clin Lab Res. 1993. PMID: 8400333 Review.

169

The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.

Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. Larsen TS, et al. Among authors: hasselbalch hc. Br J Haematol. 2007 Mar;136(5):745-51. doi: 10.1111/j.1365-2141.2007.06497.x. Br J Haematol. 2007. PMID: 17313377

170

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Eur J Haematol. 2007 Dec;79(6):508-15. doi: 10.1111/j.1600-0609.2007.00960.x. Epub 2007 Oct 23. Eur J Haematol. 2007. PMID: 17961178

171

[Novel medical treatment modalities in hematology].

Hasselbalch HC, Birgens H, Dufva IH, Dalseg AM, Brown Pde N, Jensen MK, Vangsted A. Hasselbalch HC, et al. Ugeskr Laeger. 2008 Jun 9;170(24):2115-9. Ugeskr Laeger. 2008. PMID: 18565291 Review. Danish.

172

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Hasselbalch HC, Bjørn ME. Hasselbalch HC, et al. N Engl J Med. 2015 Apr 23;372(17):1670. doi: 10.1056/NEJMc1502524. N Engl J Med. 2015. PMID: 25901433 No abstract available.

173

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Gisslinger H, et al. Among authors: hasselbalch hc. Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31. Lancet Haematol. 2020. PMID: 32014125 Clinical Trial.

174

Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study.

Pedersen KM, Çolak Y, Hasselbalch HC, Ellervik C, Nordestgaard BG, Bojesen SE. Pedersen KM, et al. Among authors: hasselbalch hc. EClinicalMedicine. 2020 Apr 6;21:100295. doi: 10.1016/j.eclinm.2020.100295. eCollection 2020 Apr. EClinicalMedicine. 2020. PMID: 32280939 Free PMC article.

175

Reconsidering 'primary myelofibrosis with increased haemoglobin' within the myeloproliferative neoplasms biological continuum.

Hasselbalch HC. Hasselbalch HC. Br J Haematol. 2025 Nov;207(5):2226-2227. doi: 10.1111/bjh.70103. Epub 2025 Aug 26. Br J Haematol. 2025. PMID: 40856246 No abstract available.

176

[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].

Larsen TS, Pallisgaard N, Christensen JH, Gram-Hansen P, Kerndrup GB, Møller MB, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2006 Sep 25;168(39):3299-303. Ugeskr Laeger. 2006. PMID: 17032592 Review. Danish.

177

Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis.

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC. Skov V, et al. Among authors: hasselbalch hc. Eur J Haematol. 2011 Jul;87(1):54-60. doi: 10.1111/j.1600-0609.2011.01618.x. Eur J Haematol. 2011. PMID: 21447007

178

Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.

Skov V, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC, Larsen TS. Skov V, et al. Among authors: hasselbalch hc. Exp Hematol. 2012 Sep;40(9):771-780.e19. doi: 10.1016/j.exphem.2012.05.011. Epub 2012 Jun 1. Exp Hematol. 2012. PMID: 22659388 Free article.

179

Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death.

Andersen CL, Siersma VD, Hasselbalch HC, Lindegaard H, Vestergaard H, Felding P, de Fine Olivarius N, Bjerrum OW. Andersen CL, et al. Among authors: hasselbalch hc. Am J Hematol. 2013 Oct;88(10):843-7. doi: 10.1002/ajh.23515. Epub 2013 Aug 1. Am J Hematol. 2013. PMID: 23765950 Free article. Clinical Trial.

180

A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms.

Brochmann N, Zwisler AD, Kjerholt M, Flachs EM, Hasselbalch HC, Andersen CL. Brochmann N, et al. Among authors: hasselbalch hc. Qual Life Res. 2016 Apr;25(4):835-46. doi: 10.1007/s11136-015-1125-1. Epub 2015 Sep 11. Qual Life Res. 2016. PMID: 26358064

181

Clonal haematopoiesis of indeterminate potential and impaired kidney function-A Danish general population study with 11 years follow-up.

Larsen MK, Skov V, Kjaer L, Møller-Palacino NA, Pedersen RK, Andersen M, Ottesen JT, Cordua S, Poulsen HE, Dahl M, Knudsen TA, Eickhardt-Dalbøge CS, Koschmieder S, Pedersen KM, Çolak Y, Bojesen SE, Nordestgaard BG, Stiehl T, Hasselbalch HC, Ellervik C. Larsen MK, et al. Among authors: hasselbalch hc. Eur J Haematol. 2022 Nov;109(5):576-585. doi: 10.1111/ejh.13845. Epub 2022 Aug 21. Eur J Haematol. 2022. PMID: 36054308 Free PMC article.

182

Metformin use and risk of myeloproliferative neoplasms: a Danish population-based case-control study.

Kristensen DT, Øvlisen AK, Jakobsen LHK, Severinsen MT, Hannig LH, Starklint J, Hilsøe MH, Vallentin AP, Brabrand M, Hasselbalch HC, El-Galaly TC, Roug AS. Kristensen DT, et al. Among authors: hasselbalch hc. Blood Adv. 2024 Aug 27;8(16):4478-4485. doi: 10.1182/bloodadvances.2023012266. Blood Adv. 2024. PMID: 38758071 Free PMC article.

183

Type III procollagen N-peptide correlates with beta-2-microglobulin in myelomatosis.

Hasselbalch HC, Bjerrum OW, Junker P. Hasselbalch HC, et al. Clin Lab Haematol. 1995 Sep;17(3):237-41. Clin Lab Haematol. 1995. PMID: 8719897

184

Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders.

Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Jensen MK, et al. Among authors: hasselbalch hc. Br J Haematol. 2000 Jul;110(1):116-24. doi: 10.1046/j.1365-2141.2000.02030.x. Br J Haematol. 2000. PMID: 10930987

185

Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area.

Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Jensen MK, et al. Among authors: hasselbalch hc. Eur J Haematol. 2000 Aug;65(2):132-9. doi: 10.1034/j.1600-0609.2000.90236.x. Eur J Haematol. 2000. PMID: 10966175

186

Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count.

Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Jensen MK, et al. Among authors: hasselbalch hc. Eur J Haematol. 2001 Mar;66(3):143-51. doi: 10.1034/j.1600-0609.2001.00359.x. Eur J Haematol. 2001. PMID: 11350482

187

Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.

Faurschou M, Hasselbalch HC, Nielsen OJ. Faurschou M, et al. Among authors: hasselbalch hc. Eur J Haematol. 2001 Jun;66(6):408-11. doi: 10.1034/j.1600-0609.2001.066006408.x. Eur J Haematol. 2001. PMID: 11488941

188

[STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia].

Hasselbalch HC. Hasselbalch HC. Ugeskr Laeger. 2002 May 27;164(22):2914-7. Ugeskr Laeger. 2002. PMID: 12082821 Review. Danish.

189

[Immunosuppressive treatment of the myelodysplastic syndrome].

Larsen MS, Hasselbalch HC. Larsen MS, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2003 Jun 23;165(26):2654-7. Ugeskr Laeger. 2003. PMID: 12886548 Danish.

190

Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism.

Jensen MK, Riisbro R, Holten-Andersen MN, Brown Pde N, Junker P, Brünner N, Hasselbalch HC. Jensen MK, et al. Among authors: hasselbalch hc. Eur J Haematol. 2003 Oct;71(4):276-82. doi: 10.1034/j.1600-0609.2003.00134.x. Eur J Haematol. 2003. PMID: 12950237

191

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.

Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC. Braendstrup P, et al. Among authors: hasselbalch hc. Am J Hematol. 2005 Apr;78(4):275-80. doi: 10.1002/ajh.20276. Am J Hematol. 2005. PMID: 15795920 Free article.

192

The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.

El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. El Fassi D, et al. Among authors: hasselbalch hc. Eur J Endocrinol. 2006 May;154(5):623-32. doi: 10.1530/eje.1.02140. Eur J Endocrinol. 2006. PMID: 16645007 Review.

193

[New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].

Larsen TS, Pallisgaard N, Christensen JH, Gram-Hansen P, Kerndrup GB, Møller MB, Hasselbalch HC. Larsen TS, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2006 Sep 25;168(39):3295-9. Ugeskr Laeger. 2006. PMID: 17032591 Review. Danish.

194

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.

El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L. El Fassi D, et al. Among authors: hasselbalch hc. J Clin Endocrinol Metab. 2007 May;92(5):1769-72. doi: 10.1210/jc.2006-2388. Epub 2007 Feb 6. J Clin Endocrinol Metab. 2007. PMID: 17284622 Clinical Trial.

195

B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.

Nielsen CH, El Fassi D, Hasselbalch HC, Bendtzen K, Hegedüs L. Nielsen CH, et al. Among authors: hasselbalch hc. Expert Opin Biol Ther. 2007 Jul;7(7):1061-78. doi: 10.1517/14712598.7.7.1061. Expert Opin Biol Ther. 2007. PMID: 17665994 Review.

196

Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia.

Stauffer Larsen T, Hasselbalch HC, Pallisgaard N, Møller MB. Stauffer Larsen T, et al. Among authors: hasselbalch hc. APMIS. 2007 Nov;115(11):1267-73. doi: 10.1111/j.1600-0643.2007.00807.x. APMIS. 2007. PMID: 18092959

197

[Aquagenic pruritus from polycythaemia vera--treatment with paroxetine, a selective serotonin reuptake inhibitor].

Kümler T, Hedlund D, Hast R, Hasselbalch HC. Kümler T, et al. Among authors: hasselbalch hc. Ugeskr Laeger. 2008 Sep 15;170(38):2981. Ugeskr Laeger. 2008. PMID: 18808757 Danish.

198

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T. Barosi G, et al. Among authors: hasselbalch hc. Blood. 2009 May 14;113(20):4829-33. doi: 10.1182/blood-2008-09-176818. Epub 2009 Mar 10. Blood. 2009. PMID: 19278953 Free article.

199

Interferon alpha2 in the treatment of hematological malignancies. Status and perspectives.

Hasselbalch HC. Hasselbalch HC. Curr Drug Targets. 2011 Mar 1;12(3):387-91. doi: 10.2174/138945011794815220. Curr Drug Targets. 2011. PMID: 21143152 No abstract available.

200

Systemic adverse events following rituximab therapy in patients with Graves' disease.

El Fassi D, Nielsen CH, Junker P, Hasselbalch HC, Hegedüs L. El Fassi D, et al. Among authors: hasselbalch hc. J Endocrinol Invest. 2011 Jul-Aug;34(7):e163-7. doi: 10.3275/7411. Epub 2010 Dec 15. J Endocrinol Invest. 2011. PMID: 21169731

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

319 results

Search Page

Filters